Compare PAGS & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PAGS | EWTX |
|---|---|---|
| Founded | 2006 | 2017 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.5B |
| IPO Year | N/A | 2021 |
| Metric | PAGS | EWTX |
|---|---|---|
| Price | $10.05 | $26.92 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 8 |
| Target Price | $11.71 | ★ $34.13 |
| AVG Volume (30 Days) | ★ 3.0M | 1.7M |
| Earning Date | 02-19-2026 | 03-02-2026 |
| Dividend Yield | ★ 1.39% | N/A |
| EPS Growth | ★ 16.68 | N/A |
| EPS | ★ 1.37 | N/A |
| Revenue | ★ $3,662,823,389.00 | N/A |
| Revenue This Year | $14.61 | N/A |
| Revenue Next Year | $5.39 | N/A |
| P/E Ratio | $7.37 | ★ N/A |
| Revenue Growth | ★ 10.88 | N/A |
| 52 Week Low | $6.50 | $10.60 |
| 52 Week High | $11.16 | $30.48 |
| Indicator | PAGS | EWTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.86 | 59.20 |
| Support Level | $9.84 | $23.57 |
| Resistance Level | $10.45 | $28.29 |
| Average True Range (ATR) | 0.36 | 1.47 |
| MACD | 0.03 | 0.22 |
| Stochastic Oscillator | 59.13 | 79.84 |
PagSeguro Digital Ltd is a Brazilian-based company that acts as a provider of financial technology solutions focused on Micro-Merchants, Small Companies and Medium-Sized Companies (SMEs), in Brazil. The company provides a range of solutions and tools such as cash-in and cash-out options and provides access to working capital to help to manage its cash flow. It delivers an end-to-end digital ecosystem to address day-to-day financial needs, including receiving and spending funds and managing and growing businesses for clients. The company also offers the Free PagSeguro Digital Account delivering Cash-In Solutions, Online and In-Person Payment Tools, Online Payment Tools; and Web Check Outs offer tokenization, handling of shipping information, and others.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.